High Patient Satisfaction with Daylight-Activated Methyl Aminolevulinate Cream in the Treatment of Multiple Actinic Keratoses: Results of an Observational Study in Australia.
Identifieur interne : 000A94 ( PubMed/Checkpoint ); précédent : 000A93; suivant : 000A95High Patient Satisfaction with Daylight-Activated Methyl Aminolevulinate Cream in the Treatment of Multiple Actinic Keratoses: Results of an Observational Study in Australia.
Auteurs : Jo-Ann See [Australie] ; Kurt Gebauer [Australie] ; Jason K. Wu [Australie] ; Shobhan Manoharan [Australie] ; Nabil Kerrouche [France] ; John Sullivan [Australie]Source :
- Dermatology and therapy [ 2193-8210 ] ; 2017.
Abstract
Actinic keratoses (AK) are treated to reduce the risk of progression to squamous cell carcinoma and for symptomatic and cosmetic benefits. The objective of this observational study was to generate real-life data on the use of daylight photodynamic therapy with methyl aminolevulinate cream (MAL DL-PDT) in treating mild to moderate facial/scalp AK.
DOI: 10.1007/s13555-017-0199-9
PubMed: 28905294
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:28905294Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">High Patient Satisfaction with Daylight-Activated Methyl Aminolevulinate Cream in the Treatment of Multiple Actinic Keratoses: Results of an Observational Study in Australia.</title><author><name sortKey="See, Jo Ann" sort="See, Jo Ann" uniqKey="See J" first="Jo-Ann" last="See">Jo-Ann See</name><affiliation wicri:level="1"><nlm:affiliation>Central Sydney Dermatology, Sydney, NSW, Australia. jsee@csdermatology.com.au.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Central Sydney Dermatology, Sydney, NSW</wicri:regionArea><wicri:noRegion>NSW</wicri:noRegion></affiliation></author><author><name sortKey="Gebauer, Kurt" sort="Gebauer, Kurt" uniqKey="Gebauer K" first="Kurt" last="Gebauer">Kurt Gebauer</name><affiliation wicri:level="1"><nlm:affiliation>Fremantle Dermatology, Perth, WA, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Fremantle Dermatology, Perth, WA</wicri:regionArea><wicri:noRegion>WA</wicri:noRegion></affiliation></author><author><name sortKey="Wu, Jason K" sort="Wu, Jason K" uniqKey="Wu J" first="Jason K" last="Wu">Jason K. Wu</name><affiliation wicri:level="1"><nlm:affiliation>Toowong Dermatology, Toowong, QLD, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Toowong Dermatology, Toowong, QLD</wicri:regionArea><wicri:noRegion>QLD</wicri:noRegion></affiliation></author><author><name sortKey="Manoharan, Shobhan" sort="Manoharan, Shobhan" uniqKey="Manoharan S" first="Shobhan" last="Manoharan">Shobhan Manoharan</name><affiliation wicri:level="1"><nlm:affiliation>Westside Dermatology, Taringa, QLD, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Westside Dermatology, Taringa, QLD</wicri:regionArea><wicri:noRegion>QLD</wicri:noRegion></affiliation></author><author><name sortKey="Kerrouche, Nabil" sort="Kerrouche, Nabil" uniqKey="Kerrouche N" first="Nabil" last="Kerrouche">Nabil Kerrouche</name><affiliation wicri:level="1"><nlm:affiliation>Galderma R&D, Sophia Antipolis, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Galderma R&D, Sophia Antipolis</wicri:regionArea><wicri:noRegion>Sophia Antipolis</wicri:noRegion><wicri:noRegion>Sophia Antipolis</wicri:noRegion></affiliation></author><author><name sortKey="Sullivan, John" sort="Sullivan, John" uniqKey="Sullivan J" first="John" last="Sullivan">John Sullivan</name><affiliation wicri:level="1"><nlm:affiliation>Kingsway Dermatology & Aesthetics, Miranda, NSW, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Kingsway Dermatology & Aesthetics, Miranda, NSW</wicri:regionArea><wicri:noRegion>NSW</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:28905294</idno><idno type="pmid">28905294</idno><idno type="doi">10.1007/s13555-017-0199-9</idno><idno type="wicri:Area/PubMed/Corpus">000496</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000496</idno><idno type="wicri:Area/PubMed/Curation">000494</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000494</idno><idno type="wicri:Area/PubMed/Checkpoint">000494</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000494</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">High Patient Satisfaction with Daylight-Activated Methyl Aminolevulinate Cream in the Treatment of Multiple Actinic Keratoses: Results of an Observational Study in Australia.</title><author><name sortKey="See, Jo Ann" sort="See, Jo Ann" uniqKey="See J" first="Jo-Ann" last="See">Jo-Ann See</name><affiliation wicri:level="1"><nlm:affiliation>Central Sydney Dermatology, Sydney, NSW, Australia. jsee@csdermatology.com.au.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Central Sydney Dermatology, Sydney, NSW</wicri:regionArea><wicri:noRegion>NSW</wicri:noRegion></affiliation></author><author><name sortKey="Gebauer, Kurt" sort="Gebauer, Kurt" uniqKey="Gebauer K" first="Kurt" last="Gebauer">Kurt Gebauer</name><affiliation wicri:level="1"><nlm:affiliation>Fremantle Dermatology, Perth, WA, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Fremantle Dermatology, Perth, WA</wicri:regionArea><wicri:noRegion>WA</wicri:noRegion></affiliation></author><author><name sortKey="Wu, Jason K" sort="Wu, Jason K" uniqKey="Wu J" first="Jason K" last="Wu">Jason K. Wu</name><affiliation wicri:level="1"><nlm:affiliation>Toowong Dermatology, Toowong, QLD, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Toowong Dermatology, Toowong, QLD</wicri:regionArea><wicri:noRegion>QLD</wicri:noRegion></affiliation></author><author><name sortKey="Manoharan, Shobhan" sort="Manoharan, Shobhan" uniqKey="Manoharan S" first="Shobhan" last="Manoharan">Shobhan Manoharan</name><affiliation wicri:level="1"><nlm:affiliation>Westside Dermatology, Taringa, QLD, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Westside Dermatology, Taringa, QLD</wicri:regionArea><wicri:noRegion>QLD</wicri:noRegion></affiliation></author><author><name sortKey="Kerrouche, Nabil" sort="Kerrouche, Nabil" uniqKey="Kerrouche N" first="Nabil" last="Kerrouche">Nabil Kerrouche</name><affiliation wicri:level="1"><nlm:affiliation>Galderma R&D, Sophia Antipolis, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Galderma R&D, Sophia Antipolis</wicri:regionArea><wicri:noRegion>Sophia Antipolis</wicri:noRegion><wicri:noRegion>Sophia Antipolis</wicri:noRegion></affiliation></author><author><name sortKey="Sullivan, John" sort="Sullivan, John" uniqKey="Sullivan J" first="John" last="Sullivan">John Sullivan</name><affiliation wicri:level="1"><nlm:affiliation>Kingsway Dermatology & Aesthetics, Miranda, NSW, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Kingsway Dermatology & Aesthetics, Miranda, NSW</wicri:regionArea><wicri:noRegion>NSW</wicri:noRegion></affiliation></author></analytic><series><title level="j">Dermatology and therapy</title><idno type="ISSN">2193-8210</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Actinic keratoses (AK) are treated to reduce the risk of progression to squamous cell carcinoma and for symptomatic and cosmetic benefits. The objective of this observational study was to generate real-life data on the use of daylight photodynamic therapy with methyl aminolevulinate cream (MAL DL-PDT) in treating mild to moderate facial/scalp AK.</div></front></TEI><pubmed><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">28905294</PMID><DateCreated><Year>2017</Year><Month>09</Month><Day>14</Day></DateCreated><DateRevised><Year>2017</Year><Month>09</Month><Day>14</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">2193-8210</ISSN><JournalIssue CitedMedium="Print"><PubDate><Year>2017</Year><Month>Sep</Month><Day>13</Day></PubDate></JournalIssue><Title>Dermatology and therapy</Title><ISOAbbreviation>Dermatol Ther (Heidelb)</ISOAbbreviation></Journal><ArticleTitle>High Patient Satisfaction with Daylight-Activated Methyl Aminolevulinate Cream in the Treatment of Multiple Actinic Keratoses: Results of an Observational Study in Australia.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1007/s13555-017-0199-9</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Actinic keratoses (AK) are treated to reduce the risk of progression to squamous cell carcinoma and for symptomatic and cosmetic benefits. The objective of this observational study was to generate real-life data on the use of daylight photodynamic therapy with methyl aminolevulinate cream (MAL DL-PDT) in treating mild to moderate facial/scalp AK.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A multicenter, prospective, observational study was conducted in Australia in patients receiving a single treatment of MAL DL-PDT for mild to moderate AK. Efficacy was assessed 3 months after treatment by investigator-assessed improvement and patient- and physician-completed satisfaction questionnaires. Adverse events were recorded throughout the study.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Overall, 81 patients were enrolled of mean age 62.7 years, mostly men (76.5%) with skin phototype I (64.2%) or II (35.8%) and a long history of AK (mean duration 16.8 years). Most had multiple lesions (82.7% had >10 lesions) of predominantly grade I (75.3%). At 3 months after treatment, almost half the patients (46.8%) required no further treatment. The proportions of patients and physicians satisfied to very satisfied with the MAL DL-PDT treatment were 79.7% and 83.3%, respectively. After receiving the treatment, 74.1% of patients indicated via the questionnaire that they were not bothered at all by the pain. Related AEs were reported in 48.1% of patients, mainly mild erythema (44.4%).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In clinical practice in Australia, the use of MAL DL-PDT in treating multiple mild to moderate non-hyperkeratotic AK of the face and/or scalp results in high levels of patient and physician satisfaction reflecting the good efficacy and tolerability of this almost painless, convenient procedure.</AbstractText><AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">ClinicalTrials.gov identifier, NCT02674048.</AbstractText><AbstractText Label="FUNDING" NlmCategory="BACKGROUND">Galderma R&D.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>See</LastName><ForeName>Jo-Ann</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Central Sydney Dermatology, Sydney, NSW, Australia. jsee@csdermatology.com.au.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gebauer</LastName><ForeName>Kurt</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Fremantle Dermatology, Perth, WA, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Jason K</ForeName><Initials>JK</Initials><AffiliationInfo><Affiliation>Toowong Dermatology, Toowong, QLD, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Manoharan</LastName><ForeName>Shobhan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Westside Dermatology, Taringa, QLD, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kerrouche</LastName><ForeName>Nabil</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Galderma R&D, Sophia Antipolis, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sullivan</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Kingsway Dermatology & Aesthetics, Miranda, NSW, Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT02674048</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>09</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Dermatol Ther (Heidelb)</MedlineTA><NlmUniqueID>101590450</NlmUniqueID></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Actinic keratosis</Keyword><Keyword MajorTopicYN="N">Australia</Keyword><Keyword MajorTopicYN="N">Daylight-activated photodynamic therapy</Keyword><Keyword MajorTopicYN="N">Methyl aminolevulinate cream</Keyword><Keyword MajorTopicYN="N">Observational study</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>07</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>9</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>9</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>9</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28905294</ArticleId><ArticleId IdType="doi">10.1007/s13555-017-0199-9</ArticleId><ArticleId IdType="pii">10.1007/s13555-017-0199-9</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Australie</li><li>France</li></country></list><tree><country name="Australie"><noRegion><name sortKey="See, Jo Ann" sort="See, Jo Ann" uniqKey="See J" first="Jo-Ann" last="See">Jo-Ann See</name></noRegion><name sortKey="Gebauer, Kurt" sort="Gebauer, Kurt" uniqKey="Gebauer K" first="Kurt" last="Gebauer">Kurt Gebauer</name><name sortKey="Manoharan, Shobhan" sort="Manoharan, Shobhan" uniqKey="Manoharan S" first="Shobhan" last="Manoharan">Shobhan Manoharan</name><name sortKey="Sullivan, John" sort="Sullivan, John" uniqKey="Sullivan J" first="John" last="Sullivan">John Sullivan</name><name sortKey="Wu, Jason K" sort="Wu, Jason K" uniqKey="Wu J" first="Jason K" last="Wu">Jason K. Wu</name></country><country name="France"><noRegion><name sortKey="Kerrouche, Nabil" sort="Kerrouche, Nabil" uniqKey="Kerrouche N" first="Nabil" last="Kerrouche">Nabil Kerrouche</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000A94 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 000A94 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:28905294
|texte= High Patient Satisfaction with Daylight-Activated Methyl Aminolevulinate Cream in the Treatment of Multiple Actinic Keratoses: Results of an Observational Study in Australia.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:28905294" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |